Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor. weiter
Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry. Building upon the success of the previous editions, this year's event gathered around 100 decision makers, renowned experts, key partners, and influential industry leaders to explore the transformative potential of radionuclides in precision oncology. weiter
Knowledge for your ears
The Life Science Learning Lab has launched a new podcast intended to spark young people’s interest in research. During the first three episodes of “scienceCLASH,” students from Berlin interviewed Sarah Kedziora and Theda Bartolomaeus from the ECRC about the gut microbiome’s influence on heart health. weiter
Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
Eckert & Ziegler SE (ISIN DE0005659700) has once again been honored with the “Best Managed Companies Award”. The award, presented by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung and the Federation of German Industries (BDI), recognize excellently managed medium-sized companies throughout Germany. Eckert & Ziegler has now received this coveted award the second time. weiter
Talk im Cube: International Cooperation and Funding programs in Life Sciences
We are excited to continue also in 2025 the Talks in the Cube starting with a further expert discussion focused on International cooperation and Funding programs in Life Sciences. weiter
Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials. weiter
Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further develop its promising lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. weiter
Event: Cutting-Edge Biomarker Profiling in clinical studies: A Lunch and Learn with CheckImmune and Olink®
A Lunch and Learn with CheckImmune and Olink® weiter
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing. weiter
“Jugend forscht” at Campus Berlin-Buch
From better 3D printers for biological structures to soil remediation with microorganisms – in the 60th round of “Jugend forscht,” regional students presented their exciting research projects on the Berlin-Buch campus. weiter
Access to high-performance computing for businesses
Helmholtz invests €18 million in AI innovation ecosystems: Nine Helmholtz centers open their High-Performance Computing infrastructure to companies and connect businesses with their AI experts. More than €2 million will go to the Max Delbrück Center. weiter
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC). weiter
Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales. weiter
FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial (‘SANTANA-225’) of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). weiter
Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced the expansion of their existing Lutetium-177 based collaboration with a global supply agreement for Actinium-225 (Ac-225). Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical research and development activities on innovative alpha radiotherapeutics. weiter
Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW
Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge diagnostic tools including 68Ga-PSMA-11 in Japan. For GalliaPharm®, Novartis Pharma K.K., will manage safety information and distribution of the product in Japan. weiter
Inspiring and connecting: “Talk im Cube”
For almost a year, “Talk im Cube” has been bringing science and business together on the Campus Berlin-Buch weiter
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the signing of a global supply agreement for the medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). weiter
Eckert & Ziegler: Changes in the Executive Board and Supervisory Board
The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment. weiter
Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). The test production demonstrated that the choice of technology was appropriate to achieve the expected parameters of the product. weiter
Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)
Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand®, by the European Commission (EC). This enables the use of the radiopharmaceutical medicinal product Theralugand® in routine clinical applications throughout the European Economic Area (EEA). weiter
Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 million or € 1.12 per share. weiter
Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its GMP grade non-carrier added Lutetium-177 chloride (n.c.a. Lu-177) for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers. weiter
Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pentixapharm AG became legally effective. All shares in Pentixapharm AG held by Eckert & Ziegler have thus been legally transferred from Eckert & Ziegler SE to Pentixapharm Holding AG. weiter
OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025 weiter
Should I Stay or Should I Go? Development Strategies for Life Science Start-Ups
Insights from ThermoFisherScientific Experts and Partners with acquisition - a Panel Discussion weiter
